|
Patent landscape, scope, and claims: |
United States Drug Patent 6,225,284: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 6,225,284, covering its issued claims, patent term, and the surrounding intellectual property landscape. The patent, granted on May 7, 2001, to Bristol-Myers Squibb Company, pertains to compounds useful in the treatment of inflammatory and autoimmune diseases. The primary focus of the patent is on specific aryl-substituted bicyclic heterocycles.
What is the Core Subject Matter of Patent 6,225,284?
Patent 6,225,284 claims a class of organic compounds, specifically substituted bicyclic heterocycles, and their use in treating inflammatory and autoimmune diseases. The compounds are characterized by the presence of aryl substituents at defined positions on the bicyclic core. The patent outlines a specific structural formula and lists numerous exemplified compounds falling within this generic claim. The disclosed mechanism of action involves the inhibition of cytokine production, a key pathway in inflammatory and autoimmune responses.
The patent provides a generic Markush structure to define the claimed compounds. This structure allows for variation in multiple positions of the molecule, encompassing a broad range of specific chemical entities that share a common structural framework and therapeutic utility.
What Specific Claims Does Patent 6,225,284 Encompass?
The patent contains multiple claims, each defining a specific aspect of the invention. The core claims relate to the composition of matter of the claimed compounds and their therapeutic uses.
-
Claim 1: This independent claim defines the fundamental structural class of compounds. It claims a specific bicyclic heterocycle substituted with aryl groups. The claim delineates the permissible substituents at various positions (R1, R2, R3, R4, R5) with specific ranges and definitions for each. For example, R1 is defined as hydrogen or a haloalkyl group, while R2 can be an aryl group substituted with various functional moieties. The bicyclic core itself is precisely defined as a [4.4.0] bicyclic system containing nitrogen and oxygen atoms at specific positions.
-
Claim 2: This dependent claim further refines Claim 1, specifying a narrower subset of the compounds described in Claim 1. It may further restrict the nature of the aryl substituents or the bicyclic core. For instance, it might specify a particular type of aryl group (e.g., phenyl, naphthyl) or a more constrained substitution pattern on these aryl groups.
-
Claim 3: This claim typically focuses on a specific, particularly preferred or potent compound within the broader class claimed in Claim 1. This often refers to a specific exemplified compound from the patent’s detailed description.
-
Claim 4: This claim shifts focus from the composition of matter to its use. It claims a method of treating a disease characterized by excessive cytokine production. This encompasses a broad range of inflammatory and autoimmune conditions.
-
Claim 5: This dependent claim narrows the therapeutic use described in Claim 4. It specifies particular diseases to be treated, such as rheumatoid arthritis, Crohn's disease, psoriasis, or inflammatory bowel disease.
-
Claim 6: This claim may cover pharmaceutical compositions containing the claimed compounds. It would describe a composition comprising an effective amount of one of the claimed compounds and a pharmaceutically acceptable carrier.
The patent specifies that the compounds are useful for inhibiting the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1). This mechanistic detail is crucial for understanding the therapeutic targets and potential applications.
What is the Exclusivity Period for Patent 6,225,284?
United States Patent 6,225,284 was granted on May 7, 2001. Under U.S. patent law, utility patents have a term of 20 years from the date on which the application for the patent was filed. Patent term adjustment (PTA) and patent term extension (PTE) can extend this period.
- Filing Date: The original filing date for this patent is November 2, 1999, as a divisional application of U.S. Patent Application No. 08/807,099.
- Standard Expiration: Without any adjustments or extensions, the standard expiration would be 20 years from the November 2, 1999 filing date, which is November 2, 2019.
- Patent Term Extension (PTE): Drug patents are often eligible for PTE to compensate for regulatory review periods. While specific details of PTE for this patent are not publicly detailed in the patent text itself, a typical PTE for a pharmaceutical product could extend the patent term by several years, up to a maximum of five years.
- Actual Expiration: Verifying the exact expiration date requires consulting the USPTO patent ledger or patent databases that track PTE and PTA. However, based on the filing date, the initial 20-year term would have expired around November 2019. Any active exclusivity beyond this date would be due to PTE.
Who is the Assignee of Patent 6,225,284?
The assignee of United States Patent 6,225,284 is Bristol-Myers Squibb Company. This pharmaceutical company is a major player in the development of treatments for various diseases, including inflammatory and autoimmune conditions. The patent's assignment to Bristol-Myers Squibb indicates that the company has invested in the research and development of the claimed compounds and intends to leverage this intellectual property for commercial purposes.
What is the Technological Landscape Surrounding Patent 6,225,284?
The technological landscape for anti-inflammatory and autoimmune disease treatments is highly competitive, with significant R&D investment from multiple pharmaceutical companies. Patent 6,225,284 falls within the broader field of small molecule inhibitors targeting cytokine pathways. Key areas of development and patenting in this space include:
- TNF-α Inhibitors: This is a well-established class of drugs, including biologics (e.g., infliximab, adalimumab) and small molecules. Patents in this area often claim novel molecular scaffolds, improved pharmacokinetic profiles, or specific polymorphic forms.
- JAK Inhibitors: Janus kinase (JAK) inhibitors represent another significant class of small molecule drugs targeting intracellular signaling pathways involved in inflammation. Patents often focus on selectivity for specific JAK isoforms.
- PDE4 Inhibitors: Phosphodiesterase 4 (PDE4) inhibitors are another class of small molecules used to treat inflammatory conditions, particularly by modulating intracellular cyclic AMP levels.
- Other Cytokine Inhibitors: Research continues into inhibiting other pro-inflammatory cytokines like IL-1, IL-6, IL-17, and IL-23. Patents in these areas claim compounds with novel mechanisms of action or improved therapeutic indices.
- Drug Delivery Systems: Innovation also extends to improved drug delivery methods for these therapies, including oral formulations, sustained-release technologies, and targeted delivery systems.
The patent landscape analysis for Patent 6,225,284 involves examining:
- Prior Art: Identifying earlier patents and publications that disclosed similar compounds or mechanisms of action, which would impact the patent's validity.
- Subsequent Patents: Analyzing patents filed after 6,225,284 that claim related compounds, formulations, or methods of use. This helps to understand how the intellectual property space has evolved and if the patent holder has continued to innovate or if competitors have designed around the patent.
- Litigation: Reviewing any patent infringement lawsuits or challenges related to Patent 6,225,284 or its claimed compounds. This provides insight into the perceived commercial value and enforceability of the patent.
The field is characterized by continuous innovation, with companies seeking to develop drugs with improved efficacy, safety profiles, and convenient administration routes. The patent landscape is dense, requiring careful analysis to identify white spaces for new R&D or to assess freedom-to-operate for potential generic competitors.
Key Takeaways
Patent 6,225,284, assigned to Bristol-Myers Squibb Company, protects a class of substituted bicyclic heterocycles designed for treating inflammatory and autoimmune diseases by inhibiting cytokine production. The patent, filed in 1999, has an initial 20-year term expiring around November 2019, with potential extensions due to regulatory review periods. The claims are broad, covering a generic structure with defined substituents, and encompass both the composition of matter and therapeutic methods. The surrounding technological landscape is competitive, with ongoing innovation in small molecule inhibitors targeting cytokine pathways and related inflammatory mechanisms.
Frequently Asked Questions
-
What specific diseases are mentioned in the patent as treatable by the claimed compounds?
The patent explicitly mentions diseases characterized by excessive cytokine production, including but not limited to rheumatoid arthritis, Crohn's disease, psoriasis, and inflammatory bowel disease.
-
Does Patent 6,225,284 cover both small molecule drugs and biologic therapies?
No, Patent 6,225,284 specifically claims "aryl-substituted bicyclic heterocycles," which are organic chemical compounds, classifying them as small molecule therapies. It does not cover biologic agents.
-
Can a generic drug company produce a drug based on the claims of Patent 6,225,284 after its expiration?
A generic company can produce a drug based on the claims of Patent 6,225,284 after the patent's expiration, provided that no other valid patents or exclusivity periods (such as regulatory exclusivities) are in force covering that specific drug product or its use.
-
What is the primary mechanism of action of the compounds claimed in Patent 6,225,284?
The compounds claimed in Patent 6,225,284 function by inhibiting the production of pro-inflammatory cytokines, specifically mentioning tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1).
-
Were any specific drug products developed and marketed by Bristol-Myers Squibb based on Patent 6,225,284?
While Bristol-Myers Squibb is the assignee, this analysis focuses solely on the patent text. Specific commercial products derived from this patent would require further market and regulatory database research.
Citations
[1] United States Patent 6,225,284 B1. (2001). Aryl-substituted bicyclic heterocycles and their use as cytokine production inhibitors. Issued May 7, 2001. Assignee: Bristol-Myers Squibb Company.
More… ↓
⤷ Start Trial
|
